BAL PHARMA
|
BAL PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 4.68 | 1.64 | 3.79 | 3.20 | -8.62 |
| CEPS(Rs) | 11.08 | 7.49 | 9.95 | 9.60 | -3.68 |
| DPS(Rs) | 1.20 | 1.00 | 1.00 | 1.00 | - |
| Book NAV/Share(Rs) | 43.84 | 40.66 | 38.92 | 35.52 | 36.99 |
| Tax Rate(%) | 17.70 | 44.84 | 37.87 | -14.86 | 4.71 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 9.35 | 8.30 | 8.53 | 9.84 | 2.94 |
| EBIT Margin(%) | 7.22 | 5.61 | 7.14 | 6.49 | -0.47 |
| Pre Tax Margin(%) | 2.67 | 1.56 | 3.27 | 1.64 | -7.91 |
| PAT Margin (%) | 2.19 | 0.86 | 2.03 | 1.88 | -7.53 |
| Cash Profit Margin (%) | 5.16 | 3.86 | 5.24 | 5.68 | -3.05 |
| Performance Ratios | |||||
| ROA(%) | 2.37 | 0.92 | 2.28 | 1.97 | -5.16 |
| ROE(%) | 11.19 | 4.31 | 10.34 | 8.97 | -21.65 |
| ROCE(%) | 12.13 | 9.56 | 12.33 | 9.72 | -0.44 |
| Asset Turnover(x) | 1.08 | 1.06 | 1.12 | 1.05 | 0.68 |
| Sales/Fixed Asset(x) | 2.56 | 2.55 | 2.60 | 2.47 | 1.83 |
| Working Capital/Sales(x) | 10.91 | 16.16 | 14.86 | 21.57 | -80.59 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.39 | 0.39 | 0.39 | 0.40 | 0.55 |
| Receivable days | 104.16 | 101.56 | 92.48 | 85.08 | 121.92 |
| Inventory Days | 99.97 | 103.42 | 87.47 | 93.31 | 146.63 |
| Payable days | 162.36 | 165.90 | 132.11 | 111.21 | 207.25 |
| Valuation Parameters | |||||
| PER(x) | 19.51 | 40.83 | 28.49 | 16.80 | - |
| PCE(x) | 8.23 | 8.94 | 10.84 | 5.60 | -8.85 |
| Price/Book(x) | 2.08 | 1.65 | 2.77 | 1.51 | 0.88 |
| Yield(%) | 1.32 | 1.49 | 0.93 | 1.86 | - |
| EV/Net Sales(x) | 0.80 | 0.75 | 0.92 | 0.74 | 0.94 |
| EV/Core EBITDA(x) | 7.83 | 8.72 | 8.86 | 7.21 | 23.47 |
| EV/EBIT(x) | 11.05 | 13.39 | 12.85 | 11.43 | -202.40 |
| EV/CE(x) | 1.30 | 1.17 | 0.99 | 0.77 | 0.68 |
| M Cap / Sales | 0.43 | 0.35 | 0.57 | 0.32 | 0.27 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 11.51 | 8.18 | 12.25 | 46.43 | -23.96 |
| Core EBITDA Growth(%) | 31.95 | -10.09 | 12.99 | 274.74 | -63.19 |
| EBIT Growth(%) | 43.52 | -15.08 | 23.56 | 2,138.47 | -106.36 |
| PAT Growth(%) | 184.26 | -54.09 | 21.07 | 136.55 | -698.78 |
| EPS Growth(%) | 185.36 | -56.70 | 18.33 | 137.11 | -422.55 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 2.01 | 2.05 | 1.80 | 2.09 | 2.26 |
| Current Ratio(x) | 1.15 | 1.09 | 1.11 | 1.08 | 0.99 |
| Quick Ratio(x) | 0.72 | 0.62 | 0.67 | 0.69 | 0.57 |
| Interest Cover(x) | 1.59 | 1.39 | 1.84 | 1.34 | -0.06 |
| Total Debt/Mcap(x) | 0.97 | 1.25 | 0.65 | 1.38 | 2.57 |
Compare Financial Ratios of peers of BAL PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| BAL PHARMA | ₹208.4 Cr | 10.2% | 0.5% | 25.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,930.0 Cr | -1.4% | -7.1% | 48% | Stock Analytics | |
| DIVIS LABORATORIES | ₹158,636.0 Cr | 1.5% | -2.1% | 63% | Stock Analytics | |
| CIPLA | ₹118,368.0 Cr | -3.5% | -5.2% | 18% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,671.4 Cr | -3.9% | -10.1% | 10.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,280.3 Cr | -0.3% | -7.3% | 52.2% | Stock Analytics | |
BAL PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| BAL PHARMA | 10.2% |
0.5% |
25.1% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
You may also like the below Video Courses
